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Abstract
Background: In a previous study we reported an 85% R1 rate for pancreatic cancer following the use
of the rigorous, fully standardized Leeds Pathology Protocol (LEEPP). As this significantly exceeded R1
rates observed by others, we investigated the reproducibility of margin assessment using the LEEPP in
a larger, prospective, observational cohort study and correlated clinicopathological data with survival.
Methods: Clinicopathological features, including exact site and multifocality of margin involvement, and
survival were collated from a prospective series of 83 pancreatoduodenectomies for pancreatic (n = 27),
ampullary (n = 24) and bile duct cancer (n = 32). Data were compared with those of the previous study in
which the same pathology protocol, based on axial slicing and extensive tissue sampling from the
circumferential margin, had been used.
Results: The R1 rate was high in pancreatic (82%) and bile duct (72%) cancer and significantly lower in
ampullary cancer (25%). Margin positivity was often multifocal, the posterior margin being most frequently
involved. Margin status correlated with survival in the entire cohort (P = 0.006) and the pancreatic
subgroup (P = 0.046). These findings were consistent with observations in our previous study.
Conclusions: Margin involvement in pancreatic cancer is a frequent and prognostically significant
finding when specimens are assessed using the LEEPP.
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Introduction
The prognosis of patients with ductal adenocarcinoma of the
pancreas is generally poor.1 The majority of patients present with
advanced disease, and only in just over 10% is the tumour ame-
nable to surgical resection. However, after surgical resection, local
recurrence is frequent and 5-year survival rates amount to only
7–25% of patients.2 Although resection margin (RM) involvement
is believed to be a critical prognostic factor in pancreatic cancer,3–7
the R1 rates reported in the literature vary from as little as 16% to
over 75%, and correlation with survival is observed in some, but
not all, studies.8–15
By contrast with rectal cancer, in which the occurrence and
prognostic significance of circumferential resection margin
(CRM) involvement has been well recognized and pathological
assessment standardized, there is currently no consensus on
detailed guidance for margin examination in pancreatoduodenec-
tomy specimens (PDEs).16
In a previous study, we reported an R1 rate of 85% for pancre-
atic cancer in a series of 54 PDEs, which had been subjected to a
fully standardized pathology examination technique according
to the Leeds Pathology Protocol (LEEPP).17 As this observation
significantly exceeded the R1 rates reported in the literature, we
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believed it important to assess whether this high R1 rate was also
found in a larger prospective series, and thus investigate the repro-
ducibility of margin status assessment according to the LEEPP. In
addition, the survival outcome based on margin status was also
determined.
Materials and methods
Patients
This was an observational study, prospective in terms of histopa-
thology data recruitment, with retrospective data analysis. The
case series consisted of 83 consecutive cancers arising in the pan-
creatic head that had been resected with curative intent between
November 2003 and April 2007 by consultant specialist surgeons
in a tertiary referral hospital. Only adenocarcinomas were
included in the study; other tumour entities, including adenocar-
cinoma arising in the context of intraductal papillary-mucinous
neoplasia or mucinous cystic neoplasia, were excluded. The tech-
nique used by the surgeons was that of a standard or pylorus
preserving PDE with standard lymphadenectomy.
The Leeds Pathology Protocol (LEEPP)
The cases were reported by a gastrointestinal pathologist (CSV),
using the LEEPP as previously described.17 In brief, after multico-
lour inking of the posterior, superior mesenteric vein (SMV)
groove and anterior surfaces of the pancreatic head, the specimen
was serially sliced in an axial plane, perpendicular to the longitu-
dinal duodenal axis (Fig. 1). The 3-dimensional tumour size, its
relationship to the key anatomical structures and the CRM were
recorded. Multiple tissue samples, including one whole mount
block, were taken from the tumour where closest to the CRM. The
trans-section margins of the duodenum/stomach, pancreatic neck
and distal bile duct (DBD) were also sampled. Microscopic
margin involvement (R1) was defined as tumour within one mil-
limetre of a resection margin, independent of the mode of tumour
spread.
Data collation
For each case the following data were collected: patient demo-
graphics; type of resection (standard or pylorus-preserving PDE);
tumour size and origin (pancreatic, ampullary or DBD); pT stage;
RM status; site of margin involvement; involvement of one or
multiple RMs; pN stage; lymph node yield; number of positive
lymph nodes, and positive lymph node rate (i.e. rate of positive to
examined lymph nodes). Survival data were obtained from the
hospital database.
Statistical analysis
Categorical data were presented as frequency and proportions,
and analysed using Fisher’s test and Pearson’s chi-squared test.
The Kaplan–Meier method was used to assess the actual survival
rate, with the date of pancreatoduodenectomy as the starting
point. Univariate analysis was performed to assess for a significant
difference in clinicopathological characteristics that influenced
overall survival following a potentially curative resection. A mul-
tivariate analysis was performed by Cox regression (stepwise
forward model) for variables significant on univariate analysis.
All statistical analyses were performed using spss for Windows™
Version 15.0 (SPSS, Inc., Chicago, IL, USA), and statistical signifi-
cance was taken at the 5% level.
Results
Demographic, operative and histopathological data
During the study period, 83 patients underwent potentially cura-
tive resection for adenocarcinoma of the pancreatic head. They
included 45 (54%) men. Median patient age at resection was 67
years (range 37–84 years). Of the 83 adenocarcinomas, 27 were
primary pancreatic, 24 ampullary and 32 of DBD origin. Fifteen of
the patients had undergone standard pancreatoduodenectomy
and 68 had undergone a pylorus-preserving procedure. There was
no significant difference in age, gender or surgical technique
between the three cancer groups.
Pancreatic and DBD cancers were predominantly stage pT3,
whereas a significant proportion of ampullary cancers were pT1
or pT2 (Table 1). Tumour size also differed significantly, with
pancreatic cancers being larger (mean 3.3 cm, range 2.0–5.5 cm;
P < 0.001) and ampullary cancers smaller (mean 1.9 cm, range
0.5–3.8 cm; P = 0.006) than DBD tumours (mean 2.5 cm, range
1.2–3.8 cm). The difference in size was significant when compar-
ing pT3 ampullary cancers with pancreatic tumours (P < 0.001),
but not when comparing either pancreatic or ampullary cancers
with DBD cancers.
The pN stage was comparable between the three cancer groups,
both for all pT stages and for the pT3 cancers (of 10 pT3 ampul-
lary cancers, nine were pN1). However, the number of positive
lymph nodes was significantly higher in the pancreatic cancer
Figure 1 Specimen dissection according to the Leeds Pathology
Protocol. Following multicolour-coded inking of the specimen
surface, pancreatoduodenectomy specimens are sliced in an axial
plane, providing a large number of specimen slices with good visu-
alization of the tumour and its relationship to key anatomical struc-
tures and the anterior, posterior and superior mesenteric vein groove
surfaces
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group (mean 4.7, range 0–14) than in the ampullary (mean 1.5,
range 0–4; P < 0.001) and DBD cancer groups (mean 2.8, range
0–7; P = 0.015). Similarly, the positive lymph node rate was sig-
nificantly higher in pancreatic cancers (mean 0.282, range 0–0.85)
than in ampullary (mean 0.097, range 0–0.30; P < 0.001) and DBD
tumours (mean 0.157, range 0–0.54; P = 0.015). These differences
remained significant when comparing pT3 cancers only. The
lymph node yield was similar in the three cancer groups (mean
17.6, range 6–32).
Resection margin involvement
Rates of margin involvement in pancreatic (22 of 27, 82%) and
DBD cancer (23 of 32, 72%) were comparable and significantly
exceeded that in the ampullary cancer group (six of 24, 25%;
P < 0.001). However, the R1 rate was higher in the pT3 subgroup
of ampullary cancers (four of 10, 40%) than in tumours in stage
pT1 or pT2 (two of 14, 14%; P = 0.045). The R1 rate pT3 ampul-
lary cancers differed significantly from that in pancreatic cancer
(P = 0.013), but showed only a trend towards divergence com-
pared with DBD cancer (P = 0.070).
Of all the clinicopathological variables, pN stage differed sig-
nificantly between R0 and R1 cases in the DBD cancer group, and
the positive lymph node rate was significantly higher in R1 than
R0 cases in all three cancer groups (Table 1).
Of the 27 pancreatic cancers, 22 were pT3N1 (81%); in the R1
subgroup the proportion of pT3N1 tumours amounted to 20 of
Table 1 Clinicopathological data
Pancreatic cancer P Ampullary cancer P DBD cancer P
R0
(n = 5)
R1
(n = 22)
R0
(n = 18)
R1
(n = 6)
R0
(n = 9)
R1
(n = 23)
Age, years
<65 2 (40%) 7 (32%) 1.000 7 (39%) 1 (17%) 0.621 3 (33%) 7 (30%) 1.000
65 3 (60%) 15 (68%) 11 (61%) 5 (83%) 6 (67%) 16 (70%)
Gender
Male 2 (40%) 8 (36%) 1.000 12 (67%) 3 (50%) 0.635 6 (67%) 14 (61%) 1.000
Female 3 (60%) 14 (64%) 6 (33%) 3 (50%) 3 (33%) 9 (39%)
Tumour size
<2.5 cm 1 (20%) 5 (23%) 1.000 13 (72%) 4 (67%) 1.000 6 (67%) 11 (48%) 0.444
2.5 cm 4 (80%) 17 (77%) 5 (28%) 2 (33%) 3 (33%) 12 (52%)
pT stagea
pT1 0 0 NA 2 (11%) 0 0.192 0 0 0.281
pT2 0 0 10 (56%) 2 (33%) 1 (11%) 0
pT3 5 (100%) 22 (100%) 6 (33%) 4 (67%) 8 (89%) 23 (100%)
pN stage
N0 2 (40%) 2 (9%) 0.144 8 (44%) 0 0.066 5 (56%) 3 (13%) 0.023
N1 3 (60%) 20 (91%) 10 (56%) 6 (100%) 4 (44%) 20 (87%)
Number of positive lymph nodesb 4 (80%) 11 (50%) 0.342 11 (61%) 1 (17%) 0.155 7 (78%) 9 (39%) 0.113
1 (20%) 11 (50%) 7 (39%) 5 (83%) 2 (22%) 14 (61%)
Positive lymph node ratec 4 (80%) 6 (27%) 0.047 10 (56%) 0 0.024 6 (67%) 5 (22%) 0.035
1 (20%) 16 (73%) 8 (44%) 6 (100%) 3 (33%) 18 (78%)
Margin involvedd
Posterior NA 13 NA NA 5 NA NA 21 NA
SMVgroove 12 1 7
Anterior 3 1 0
Trans-section 3 0 0
Multiple 8 1 5
DBD, distal bile duct; NA, not applicable; SMV, superior mesenteric vein
aAnalysis was performed comparing patients with pT1 or pT2 cancers with those with pT3 tumours
bNumbers of positive lymph nodes were compared between the R0 and R1 groups using the following cut-off values: pancreatic cancer (<5 vs. 5);
ampullary cancer (1 vs. >1), and DBD cancer (2 vs. >2)
cLymph node positivity rates were compared between the R0 and R1 groups using the following cut-off values: pancreatic cancer (0.1 vs. >0.1);
ampullary cancer (0.05 vs. >0.05), and DBD cancer (0.05 vs. >0.05)
dBecause of the multifocality of margin involvement in some cases, the number of involved margins exceeds the total number of R1 cases
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22 (91%). Near identical observations were made in the DBD
group (24 of 32 were pT3N1, 75%) and the corresponding R1
subgroup (20 of 23, 87%).
In the three cancer groups, the posterior CRM was most fre-
quently involved, followed by the SMV groove margin (Table 1).
The anterior surface was involved in four of the total of 28 pan-
creatic and ampullary cancer cases with RM involvement, but in
none of the DBD cancers. Involvement of the pancreatic trans-
section margin was observed in only three pancreatic cancers, all
of which also had a positive CRM.
Adjuvant treatment
All patients in the cohort were referred for consideration of adju-
vant treatment, and 20 patients went on to receive chemotherapy
(eight pancreatic, three ampullary, nine DBD cancers). Survival
analysis for adjuvant chemotherapy was not performed because of
the small number of patients in each cancer subgroup.
Survival
All patients were included in the survival analysis. The operative
mortality rate (30 days) was 3.6% for the entire cohort. Median
follow-up was 18 months (range 10–55 months), during which 42
patients died of recurrent disease. The overall 1-, 3- and 5-year
actual survival rates for the entire cohort were 74%, 38% and 33%,
respectively. The difference in survival following R0 and R1 resec-
tion was significant for the entire cohort (P = 0.006).
Of the 27 patients with pancreatic cancer, 17 died; none of these
were postoperative deaths. The median follow-up of the remain-
ing patients was 16.5 months (range 12–55 months). Overall 1-, 3-
and 5-year survival rates following resection were 67%, 25% and
25%, respectively. There was a significant difference in survival
between patients who underwent R0 resections compared with
patients with tumour involvement of the RM (P = 0.046). The
median survival of R1 pancreatic cancer patients was 14 months,
whereas at 55-months follow-up, the median survival of the R0
pancreatic cancer group had not yet been identified (four of five
patients were alive) (Fig. 2). No other clinicopathological vari-
ables achieved significance with respect to survival (Table 2).
Of the 24 patients with ampullary cancer, eight died; one of
these represented a postoperative death. The remaining patients
had a median follow-up of 25 months (range 11–50 months). The
overall 1-, 3- and 5-year survival rates following resection were
79%, 69% and 55%, respectively. There were no clinicopathologi-
cal variables that influenced overall survival (Table 2).
Of the 32 patients with DBD cancer, 17 died, two of which
represented postoperative deaths. The median follow-up of the
remaining patients was 13 months (range 10–49 months). Overall
1-, 3- and 5-year survival rates following resection were 75%, 24%
and 24%, respectively. Similarly to the ampullary cancer group,
none of the clinicopathological factors affected overall survival
(Table 2).
In summary, based on the univariate analysis of these three
subgroups, only RM status had an impact on survival in the pan-
creatic cancer group. None of the other clinicopathological factors
influenced prognosis in the pancreatic, ampullary or DBD cancer
subgroups and hence no multivariate analysis was performed.
Discussion
Although RM involvement is recognized as an important prog-
nostic factor in pancreatic cancer, there is currently no standard-
ization of the histopathological examination technique and
reporting of PDEs.16 In a previous study, we demonstrated that
standardization of the histopathological technique by implement-
ing the LEEPP influences the reporting of RM status and allows a
better correlation between histological staging and outcome in
pancreatic cancer.17 In the present study, the LEEPP was prospec-
tively applied to a larger cohort to assess the reproducibility of
findings.
The case series that formed the basis of the current study was
comparable with that previously analysed in terms of patient age
and gender, T-stage distribution in the pancreatic, ampullary and
DBD cancer groups, and surgical technique.17
The R1 rate for pancreatic cancer in the current study was
nearly identical (82%) to that previously reported, and a similar
R1 rate was recorded for ampullary cancer (25%; 27% in the
previous study).17 A recent study from Heidelberg has shown
similar results, with an R1 rate for pancreatic adenocarcinoma
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Figure 2 Survival of patients with pancreatic cancer. The actual sur-
vival curve for the 27 patients with pancreatic cancer shows that
patients who underwent an R0 resection had a significantly better
outcome than those in whom an R1 resection was performed (P =
0.046)
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using a standardized protocol of 76%.18 Interestingly, the R1 rate
for DBD cancer (72%) exceeded that reported in the previous
study (46%). The reason for this difference is not clear; however,
two factors are likely to be responsible. Firstly, the previous study
was based on a smaller series, which contained a lower number of
DBD cancers (13 of 54, 24%) than the current cohort (32 of 83,
39%; P = 0.07). Secondly, the DBD tumours in the current series
(mean 2.5 0.7 cm) were significantly larger than in the previous
series (mean 1.9  0.6 cm; P = 0.003). The increase in relative
incidence and size of DBD cancers is most likely attributable to
chance because the selection criteria for surgery remained unal-
tered during both study periods.
Based on the current findings, the R1 rate in pancreatic cancer
did not significantly differ from that in DBD cancer, despite the
fact that tumour size was considerably smaller in the DBD cancer
group. The high rate of margin involvement in DBD cancer,
despite the smaller tumour size, probably results from the ana-
tomical position of the DBD in PDEs, particularly its proximity to
the posterior CRM and the propinquity of the proximal portion of
the DBD to the SMV groove margin.
The R1 rate in ampullary carcinoma was significantly lower
than that in pancreatic or DBD cancer. However, analysis of the
ampullary cancer group showed that the rate of margin involve-
ment in pT3 cancers differed only from that in pancreatic cancer
(P = 0.013), not that in DBD tumours (P = 0.069). The latter
finding may be explained by the similar size of pT3 ampullary
cancers and DBD tumours.
The incidence of the site of margin involvement was also strik-
ingly similar in both studies. In the current study, as in the previ-
ous series, the margins most commonly reported positive were the
posterior (75% and 66%, respectively) and SMV groove CRM
(39% and 44%, respectively), whereas the anterior surface was
involved in only a limited number of cases (8% and 22%, respec-
tively). The latter finding is in line with results from Japanese
studies, which reported involvement of the anterior surface in
20% of cases and correlation with 5-year survival.19,20 The obser-
vations in the current study indicate that the site of CRM involve-
ment depended on the tumour origin and size. The SMV groove
margin, which is anatomically the most remote from the ampul-
lary region, was positive in only a single ampullary case, which was
by far the largest tumour (3.8 cm) in the ampullary cancer group
(median size 1.9 cm, range 0.5–3.8 cm). Similarly, the distances
between the anterior and posterior surfaces of PDEs, which vary
between 3.0 cm and 4.5 cm, and the different anatomical position
and range of tumour sizes in the three cancer groups seem to
explain why the anterior surface was involved in some of the
pancreatic and ampullary cancers, but in none of the DBD
tumours.
Similarly to findings in the previous study, a significant propor-
tion of cases in the current series showed multifocal involvement
of the CRM (28 vs. 44%; P = 0.114). The low rate of involvement
of the trans-section margin at the pancreatic neck (6% in both
series) may reflect the use of intraoperative frozen-section exami-
nation of that margin. Frozen-section examination of the pancre-
atic neck trans-section margin, although not performed routinely,
was useful in tumours located close to the neck of the pancreas as,
if the margin were positive, the resection could be extended more
laterally to achieve a negative margin. However, in terms of other
margins, particularly the CRM, frozen-section examination does
not add any advantage, because even if the margin is positive there
is no scope to resect any more tissue, as the limit of dissection has
already been reached. Information on exactly which RM is
involved allows for speculation on the probable R1 rate if only the
pancreatic trans-section margin and the SMV groove CRM are
examined, as is routine practice in some countries,9 rather than
the entire specimen surface, as stipulated in the LEEPP.
In addition to the fore-mentioned striking similarities in
reported R1 rates for pancreatic and ampullary cancer and the
Table 2 Univariate survival analysis
Clinicopathological factors Survival analysis, P-value
Pancreatic cancer Ampullary cancer DBD cancer
Age 65 years 0.782 0.216 0.638
Male gender 0.177 0.871 0.812
Tumour size 0.908 0.753 0.784
pT stagea NA 0.856 NA
pN stage 0.495 0.371 0.593
Number of positive lymph nodesb 0.499 0.945 0.384
Positive lymph node ratec 0.867 0.695 0.295
Resection margin status 0.046 0.252 0.871
DBD, distal bile duct
aAnalysis was performed comparing patients with pT1 or pT2 cancers with those with pT3 tumours
bAnalysis of the impact of the number of positive lymph nodes on survival was performed for the following cut-off values: pancreatic cancer (<5 vs.
5); ampullary cancer (1 vs. >1), and DBD cancer (2 vs. >2)
cAnalysis of the impact of the positive lymph node rate on survival was performed for the following cut-off values: pancreatic cancer (0.1 vs. >0.1);
ampullary cancer (0.05 vs. >0.05), and DBD cancer (0.05 vs. >0.05)
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site of margin involvement, lymph node status in the current
series was also found to be comparable with that observed in the
previous study, both for the overall cohort and the three cancer
groups. Compared with published data, the pN1 rate in this
study is high, even if corrected for pT stage.21,22 This may be
related to the high lymph node yield from the PDEs in this study
and the good visualization of peripancreatic lymph nodes facili-
tated by the axial slicing technique specified in the LEEPP. The
positive lymph node rate, which is a more accurate indicator of
the extent of metastatic lymph node spread,23,24 correlated sig-
nificantly with RM status, indicating that involvement of both
lymph nodes and RMs is a feature of advanced tumour progres-
sion. The vast majority of pancreatic cancers were indeed pT3
tumours with a full house of prognostically adverse factors (83%
pT3N1, 74% pT3N1R1).
Taken together, the results of this study indicate that standard-
ization of the pathology examination technique results in the
reproducible reporting of data related to margin involvement and
lymph node metastasis in pancreatic head cancer. Most impor-
tantly, this study demonstrates that implementing the LEEPP
results in a constant finding of a margin involvement rate of
80% in PDEs for pancreatic cancer. It is likely that a non-
standardized approach accounts, at least in part, for the wide
variation in R1 rates – 16–75% – that have been published for
ductal adenocarcinoma of the pancreas.8–15
Critical review of survival data of pancreatic cancer patients
reveals incongruence between the reported R1 rate and clinical
outcome.16 The high local recurrence rate of pancreatic cancer –
usually reported at 67–86%9,25–27 – seems to conflict with an R1
rate that, in the majority of published reports, lies below 30–40%.
Survival figures in series with low R1 rates are not significantly
different from those with higher R1 rates,2,8,17,28 and the survival
benefit of R0 vs. R1 resection is often small, at 4–8 months, and
statistically non-significant.5,8,9,11,14,29–32
The overall survival rates for patients with pancreatic, ampul-
lary and DBD cancer in this study are comparable with reported
values, despite the higher R1 rate observed in this series.1,2,6 Analy-
sis of the entire cohort, irrespective of the site of cancer origin,
demonstrated that patients with a clear RM (R0) had significantly
better overall survival (P = 0.006). Analysis of the pancreatic
cancer subgroup revealed margin status as the only significant
prognostic factor influencing survival following surgical resection
(P = 0.046). Although the number of R0 pancreatic cancer cases
was small in this study, median survival had not yet been reached
at 55 months follow-up and has exceeded that of other studies, in
which the median survival of this particular subgroup has been
reported as 8–32 months.5,12,15,27,32–35 A similar survival benefit of
R0 resection of pancreatic cancer was found in our previous study,
which was based on the same pathological protocol.17 In patients
with ampullary or DBD cancer, none of the clinicopathological
variables were found to influence survival.
The high R1 rate suggests that although these tumours are
technically resectable, their more threatening biology cannot be
resolved by more aggressive surgery, but requires, perhaps, newer
targeted neoadjuvant therapies or better adjuvant treatment fol-
lowing surgery.
In conclusion, this study confirms that application of the
LEEPP allows for accurate reporting of RM status, which corre-
lates with a clear survival benefit for patients who undergo R0
resection of pancreatic cancer.
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